ABSTRACT
Introduction Bipolar disorder is a complex psychiatric condition with distinctions between clinical subtypes including Type 1 and 2 disorders. Several studies have proposed thyroid hormones may be involved in the etiology of bipolar disorders.
Methods This study employed a two-sample Mendelian Randomization (MR) approach to investigate the causal relationships between six thyroid hormone metrics (TSH, FT4, FT3, TT3, FT3/FT4, and TT3/FT4) and bipolar disorder, and Type 1 and 2 disorders, separately. Genome-wide association (GWAS) data from the Thyroidomics Consortium (up to 271,040 individuals of European ancestry) were used for thyroid function metrics. Bipolar disorder GWAS data included 41,917 cases and 371,549 controls (25,060 Type 1 and 6,781 Type 2 cases). We applied inverse variance weighted (IVW) methods for primary MR analysis, with MR Egger, weighted median, and weighted mode for sensitivity. Additional tests assessed horizontal pleiotropy and heterogeneity.
Results Higher FT4 levels showed a protective causal effect against bipolar disorder (OR: 0.92, 95% CI: 0.86-0.97, p=4.58×10−3) and a suggestive effect on Type 1 disorders (OR: 0.92, 95% CI: 0.86-0.99, p=3.21×10−2). Elevated FT3 (OR: 1.18, 95% CI: 1.03-1.35, p=1.55×10−2) and FT3/FT4 ratio (OR: 1.97, 95% CI: 1.02-3.82, p=4.46×10−2) had suggestive harmful effects on Type 1 disorders. Sensitivity analyses showed consistent effects, with no significant horizontal pleiotropy or heterogeneity.
Conclusions These findings highlight the protective role of FT4 and the potentially harmful effect of elevated FT3 in Type 1 bipolar disorder, highlighting the need for further research on thyroid hormone levels as a potential treatment strategy for Type 1 bipolar disorder.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health (award number T32GM007281) and the Susan G. Komen Breast Cancer Foundation (TREND21675016 and SAC210203).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All GWAS summary statistics utilized in this study are previously published and publicly available and for academic use without restriction. GWAS summary statistics for thyroid function utilized in this study are downloadable from the Thyroidomics Consortium at https://transfer.sysepi.medizin.uni-greifswald.de/thyroidomics/datasets/. GWAS summary statistics for bipolar disorders utilized in this study are downloadable from the Psychiatric Genomics Consortium at https://pgc.unc.edu/for-researchers/download-results/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Code for all analyses performed in this study are available at https://github.com/james-li-projects/MR_Thyroid_BPD.
